UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2019
CHEMBIO DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
3661 Horseblock Road, Medford, New York 11763
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (631) 924-1135
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 |
Other Events
|
Automated Manufacturing Line
Consistent with our previously announced intention to begin automated production of our DPP tests by the end of the first quarter of 2019, we commenced production of
DPP tests on a new, fully automated manufacturing line in March 2019.
DPP is our registered trademark. For convenience, this trademark appears in this Current Report on Form 8-K without ® symbols, but that
practice does not mean that we will not assert, to the fullest extent under applicable law, our rights to the trademark.
Development of Diagnostic Test for Mild Traumatic
Brain Injury
On April 2, 2019, we announced that we had entered into an agreement with Perseus Science Group LLC to advance the development of a diagnostic test for
mild traumatic brain injury, or concussion. We issued a press release titled “Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test,” a copy of which is included as Exhibit 99.1 to this Current Report
on Form 8-K.
| Item 9.01 |
Financial Statements and Exhibits
|
(d) Exhibits.
|
Exhibit
|
Description
|
|
|
Press release of Chembio Diagnostics, Inc. dated April 2, 2019
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf
by the undersigned hereunto duly authorized.
|
CHEMBIO DIAGNOSTICS, INC.
|
||
|
Dated: April 2, 2019
|
By:
|
/s/ John J. Sperzel III
|
|
John J. Sperzel III
|
||
|
Chief Executive Officer and President
|
||